The Technical Analyst
Alterity Therapeutics [ATHE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Alterity Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
9.61% $2.51
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 20.57 mill |
| EPS: | -2.10 |
| P/E: | -1.200 |
| Earnings Date: | Aug 30, 2024 |
| SharesOutstanding: | 8.20 mill |
| Avg Daily Volume: | 0.0840 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | n/a | n/a | n/a | n/a | ||
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.200 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.20x |
| Company: PE -1.200 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0564 (-102.25%) $-2.57 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.38 - 2.64 ( +/- 5.18%) |
| ATR Model: 14 days |
Forecast:
16:00 - $2.51
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.51
Forecast 2: 16:00 - $2.51
Forecast 3: 16:00 - $2.51
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.51 (9.61% ) |
| Volume | 0.0877 mill |
| Avg. Vol. | 0.0840 mill |
| % of Avg. Vol | 104.43 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ATHE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 14:37 | buy | $1.950 | N/A | Active |
|---|
ATHE
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Latest Press Releases
2024-04-17 07:25:00 - Press Release
Alterity Therapeutics Parkinson's Disease And Multiple System Atrophy Data Featured At The American Academy Of Neurology (aan) 2024 Annual Meeting
– ath434 improved motor performance and general function in a primate model of parkinson's disease – – ath434-201 phase 2 baseline data confirm approach to target biomarkers for slowing disease progression – – 12-month data from biomuse study shows key biomarker is associated with disease progression in msa – melbourne, australia and san francisco, april 17, 2024 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters were presented at the american academy of neurology (aan) 2024 annual meeting taking place april 13-18, 2024, in denver, colorado, usa...
2024-04-10 07:25:00 - Press Release
Alterity Therapeutics To Present New Data On Ath434 At The World Orphan Drug Congress Usa 2024
Melbourne, australia and san francisco, april 10, 2024 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data on ath434 will be presented at the world orphan drug congress usa 2024 taking place april 23-25, 2024 in boston, ma.
2024-03-26 10:25:00 - Press Release
Alterity Therapeutics Receives A A$3.9 Million Research & Development Tax Incentive Refund
Melbourne, australia and san francisco, march 27, 2024 (globe newswire) -- alterity therapeutics limited (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a a$3.9 million cash refund from the australian taxation office under the australian government's research and development tax incentive (r&dti) scheme.
2024-02-20 10:25:00 - Press Release
Alterity Therapeutics To Present New Data At The Upcoming American Academy Of Neurology 2024 Annual Meeting
– positive efficacy data for ath434 in a primate model of parkinson's disease to be presented at international conference –
2024-02-06 07:25:00 - Press Release
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial As Planned After Second Review
- ath434-201 trial on track to complete in november 2024 – - top-line data expected in january 2025 - melbourne, australia and san francisco, feb. 06, 2024 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent data monitoring committee (dmc) has completed its second review of trial data and recommended the ath434-201 phase 2 study continue as planned. the ath434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ath434 in patients with early-stage multiple system atrophy (msa), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.
Latest News
2024-04-10 07:25:00 - GlobeNewsWire
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23-25, 2024 in Boston, MA.
2024-02-20 10:25:00 - GlobeNewsWire
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease to be Presented at International Conference –
2023-12-05 15:02:16 - Zacks Investment Research
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
2023-12-04 16:35:00 - GlobeNewsWire
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast on Wednesday, 6 December 2023 in Australia / Tuesday, 5 December 2023 in the United States. Details are listed below and registration is required.
2023-12-04 14:15:25 - InvestorPlace
Why Is Alterity Therapeutics (ATHE) Stock Up 150% Today?
Shares of Alterity Therapeutics (NASDAQ: ATHE ) — which specializes in neurodegenerative diseases and neurological disorders — are skyrocketing today. Undergirding sentiment on Monday is groundbreaking research regarding Parkinson's disease (PD) in primates.
2023-12-04 10:58:07 - Investors Business Daily
Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial Data
Shares in Alterity Therapeutics soared after the biotech firm disclosed promising new clinical trial data for its Parkinson's disease treatment.
2023-06-21 07:25:00 - GlobeNewsWire
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
MELBOURNE, Australia and SAN FRANCISCO, June 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present a corporate overview and participate in a Q&A discussion at the MST Access Rare Diseases, Rich Returns Forum on Thursday, 22 June 2023 at 10:30 a.m. AEST (Wednesday, 21 June 2023 at 5:30 p.m. Pacific Time).
2023-05-19 07:25:00 - GlobeNewsWire
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
MELBOURNE, Australia and SAN FRANCISCO, May 19, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present at the SHARE Series Monday Management Update on Monday, May 22, 2023, at 11:00 am ET or 1:00am AEST Tuesday, May 23, 2023.
2022-01-28 11:02:33 - Benzinga
Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Disease
Alterity Therapeutics's ATHE data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease. [ALERT[ Matt Maley just released his latest pick with an upside of over 100% in 2 years.
2022-01-06 09:40:20 - PennyStocks
Hot Penny Stocks to Watch Right Now That Are Moving in Premarket
These penny stocks climbed during premarket trading, here's why The post Hot Penny Stocks to Watch Right Now That Are Moving in Premarket appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.